enGene Therapeutics (ENGN) Net Cash Flow (2023 - 2026)

enGene Therapeutics (ENGN) has 4 years of Net Cash Flow data on file, last reported at $11.2 million in Q3 2026.

• For the quarter ending Q3 2026, Net Cash Flow rose 144.93% year-over-year to $11.2 million; the trailing twelve-month figure through Jul 2026 stood at $8.4 million (up 103.73% YoY), and the FY2025 full-year result was -$122.9 million, down 234.29% from the prior year.
• Net Cash Flow was $11.2 million for Q3 2026 at enGene Therapeutics, up from -$6.8 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $179.2 million in Q2 2024 to a low of -$110.7 million in Q1 2025.
• A 4-year average of $1.4 million and a median of -$4.8 million in 2025 frame the typical range for Net Cash Flow.
• Across the five-year window, Net Cash Flow jumped 5314.45% in 2024 and slumped 2783.29% in 2025, its largest moves.
• enGene Therapeutics' Net Cash Flow stood at $43.9 million in 2023, then plunged by 292.76% to -$84.7 million in 2024, then surged by 120.7% to $17.5 million in 2025, then sank by 36.12% to $11.2 million in 2026.
• Per Business Quant data, the three most recent Net Cash Flow figures were $11.2 million in Q3 2026, -$6.8 million in Q2 2026, and -$13.5 million in Q1 2026.